# GSK Blenrep granted Breakthrough Therapy Designation by China’s CDE

- Link: https://www.directorstalkinterviews.com/gsk-blenrep-granted-breakthrough-therapy-designation-by-chinas-cde/4121171342
- Published: 2024-09-13T08:13:10+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**
has announced that the Center for Drug Evaluation (CDE) of the National Medical 
Products Administration (NMPA) in China has granted Breakthrough Therapy Designation(
BTD) for _Blenrep_ (belantamab mafodotin) combined with bortezomib plus dexamethasone(
BorDex) for the treatment of relapsed or refractory multiple myeloma. NMPA BTD is
intended to expedite the development of therapies for serious and life-threatening
diseases for which there are no existing treatments or where initial evidence has
shown an improvement in patient outcomes over available treatment options.^([2])

 * Granted based on results from phase III head-to-head DREAMM-7 trial
 * Designation expedites development of investigational drugs with potential for
   substantial improvement over available therapies
 * Novel therapies needed in multiple myeloma as patients typically relapse or stop
   responding to initial treatments^([1])

> **Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said:**“
> Breakthrough Therapy Designation in China underscores the potential for _Blenrep_
> to redefine outcomes for patients with multiple myeloma at or after their first
> relapse. We look forward to continuing to work with the health authority in China
> and others worldwide to bring _Blenrep_-based combinations to patients as expeditiously
> as possible.”

BTD was granted based on the interim results of the phase III head-to-head DREAMM-
7 trial, which met its primary endpoint, showing statistically significant and clinically
meaningful improvements in progression-free survival (PFS) for belantamab mafodotin
combined with BorDex compared to daratumumab plus BorDex in relapsed or refractory
multiple myeloma.

A positive overall survival (OS) trend was observed but was not statistically significant
at the time of interim analysis. Follow-up for OS continues. Results also showed
clinically meaningful improvements across all other secondary efficacy endpoints,
including deeper and more durable responses compared to the standard of care combinations.
The safety and tolerability profile of the belantamab mafodotin combination in the
DREAMM-7 trial was broadly consistent with the known profiles of the individual 
agents.

Multiple myeloma is a growing health concern in China with approximately 30,000 
new cases each year^([3]). The incidence in China has doubled and mortality has 
increased 1.5-fold in the past three decades.^([4]) This underscores the need for
novel, efficacious treatment options for patients in China, particularly those with
progressing disease that has become resistant to the current standard of care.

**GSK in oncology**

Oncology is an emerging therapeutic area for GSK where we are committed to maximising
patient survival with a current focus on haematologic malignancies, gynaecologic
cancers, and other solid tumours through breakthroughs in immuno-oncology and tumour-
cell targeting therapies.

---

^([1]) Moreau P., Kumar S, San Miguel J, et al. Treatment of relapsed and refractory
multiple myeloma: recommendations from the International Myeloma Working Group. 
The Lancet Oncology, Volume 22, Issue 3, e105-e118.doi:10.1016/S1470-2045(20)30756-
7.

^([2]) China Drug Registration Regulation. Available at: http://www.gov.cn/gongbao/
content/2020/content_5512563.htm. Accessed 12 September 2024.

^([3]) Global Cancer Observatory. International Agency for Research on Cancer. World
Health Organization. China fact sheet. Available at: https://gco.iarc.who.int/media/
globocan/factsheets/populations/160-china-fact-sheet.pdf. Accessed 12 September 
2024.

^([4]) Liu J, Liu W, Mi L, et al. Burden of multiple myeloma in China: an analysis
of the Global Burden of Disease, Injuries, and Risk Factors Study 2019. Chin Med
J (Engl). 2023;136(23):2834-2838. Published 2023 Dec 5. doi:10.1097/CM9.0000000000002600.

Share on:
